The Evolution of Antibodies into Versatile Tumor-Targeting Agents
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
In recent years, monoclonal antibodies have become important weapons in the arsenal of anticancer drugs, and in select cases are now the drugs of choice due to their favorable toxicity profiles. Originally developed to confer passive immunity against tumor-specific antigens, clinical uses of monoclonal antibodies are expanding to include growth factor sequestration, signal transduction modulation, and tumor-specific drug delivery. In this review, we shall present the origins of antibody therapeutics within the field of immunotherapy and their evolution into effective anticancer agents, then discuss their multiple mechanisms of action, the basis of their tumor selectivity, and their therapeutic properties compared with traditional therapies. Antibodies are complex molecules whose efficacy and toxicity depend on the antigen, the antibody, any conjugated groups, and even the patient. Finally, we shall present new technologies being developed to increase the efficacy and selectivity of antibody-based therapeutics. Interestingly, many of the new approaches straddle the middle ground between immunotherapy and the traditional modalities of chemotherapy and radiotherapy, and can be seen as ways of combining the selectivity of the former with the efficacy of the latter.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Tong, X., O'Kelly, J., Xie, D., Mori, A., Lemp, N., McKenna, R., Miller, C. W., & Koeffler, H. P. (2004) · Oncogene · doi:10.1038/sj.onc.1207628 · Cited by 86
RetractedCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells.
Lau, L. F., & Nathans, D. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb04057.x · Cited by 567
Babic, A. M., Kireeva, M. L., Kolesnikova, T. V., & Lau, L. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6355 · Cited by 495
Leu, S.-J., Lam, S. C.-T., & Lau, L. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209288200 · Cited by 247
Cited by
Tasciotti, E., Liu, X., Bhavane, R., Plant, K., Leonard, A. D., Price, B. K., Cheng, M. M.-C., Decuzzi, P., Tour, J. M., Robertson, F., et al. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2008.34 · Cited by 668
All in the CCN family: essential matricellular signaling modulators emerge from the bunker
Leask, A., & Abraham, D. J. (2006) · Journal of Cell Science · doi:10.1242/jcs.03270 · Cited by 655
A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer
Jiao, S., Wang, H., Shi, Z., Dong, A., Zhang, W., Song, X., He, F., Wang, Y., Zhang, Z., Wang, W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.010 · Cited by 602
Lai, D., Ho, K. C., Hao, Y., & Yang, X. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2711 · Cited by 416
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Metadata
- Authors
- Lin, M. Z., Teitell, M. A., & Schiller, G. J.
- Venue
- Clinical Cancer Research
- Published
- 2005-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 129-138
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2171595654
- Cited by
- 136
- References
- 17
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Evolution of Antibodies into Versatile Tumor-Targeting Agents. https://app.cochat.ai/papers/10.1158/1078-0432.129.11.1
- The paper
- Lin, M. Z., Teitell, M. A., & Schiller, G. J. (2005). The Evolution of Antibodies into Versatile Tumor-Targeting Agents. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.129.11.1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.